Zealand Pharma — November 2022
-
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
Press release – No. 7 / 2022Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
Results from the phase 2 clinical trial of GCGR/GLP-1R dual agonist BI 456906 showing bodyweight reductions of up to 9% after 16 weeks in people with type 2 diabetes to be presented
Four preclinical presentations highlighting effects of Zealand Pharma’s three wholly owned peptide therapeutic candidates (dapigluti
-
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting (inkl. link):
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
Press release – No. 7 / 2022 Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting Results from the phase 2 clinical trial of...
GlobeNewswire News Room (www.globenewswire.com)
-
Zealand leverer vægttabsdata for middel under Boehringer-samarbejde https://www.proinvestor.com/investornyt
/898309/zealand-leverer-vaegttabsdata-for-middel-under-boehringer-samarbejde -
"I et fase 2-studiet har lægemiddelkandidaten vist sig at kunne give vægttab på op til 9 pct. efter 16 uger i type 2-diabetikere. Til sammenligning havde patienter på Novos GLP-1-middel Semaglutid et vægttab på 5,4 pct. i et åbent studie, hvor patienter og læger vidste, hvilket middel de fik"
. -
Zealand Pharma leverer vægttabsdata for middel under Boehringer-samarbejde
Zealand Pharma leverer vægttabsdata for middel under Boehringer-samarbejde
Zealand Pharma offentliggør i denne uge data fra et studie af selskabets nye lægemiddel, der er den del af samarbejdet med Boehringer Ingelheim, som står for udviklingen af lægemidlet.
(medwatch.dk)
"Zealand Pharma offentliggør i denne uge data fra et studie af selskabets nye lægemiddel, der er den del af samarbejdet med Boehringer Ingelheim, som står for udviklingen af lægemidlet."
-
Hør eller genhør Adam Steensberg glæde over fedmepipelinen:
https://www.proinvestor.com/boards/106849?fbclid=IwAR3IFq-c8vM5cgIPd9-oo1NgzTwKQJsqlpdAXSU2JvwfoCmTUSm2gPerbSU -
Debattråd: https://www.proinvestor.com/boards/107439
-
-
Godmorgen
-
Godmorgen
-
Det er vist jul i november:)
-
underlig start i den
-
Helt enig ST. Tror at nyheden drukner i kølvandet på Novos regnskab m.m.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind